

**From:** Beel, Bryan D. (Perkins Coie) <[BBeel@perkinscoie.com](mailto:BBeel@perkinscoie.com)>  
**Sent:** Monday, November 20, 2023 3:43 PM  
**To:** Megan Raymond <[megan.raymond@groombridgewu.com](mailto:megan.raymond@groombridgewu.com)>  
**Cc:** [Novo-Semaglutide-IPR@groombridgewu.com](mailto:Novo-Semaglutide-IPR@groombridgewu.com); White, Brandon (Perkins Coie) <[BMWhite@perkinscoie.com](mailto:BMWhite@perkinscoie.com)>; [White-ptab@perkinscoie.com](mailto:White-ptab@perkinscoie.com); [Greb-ptab@perkinscoie.com](mailto:Greb-ptab@perkinscoie.com); [prochnow-ptab@perkinscoie.com](mailto:prochnow-ptab@perkinscoie.com); [jones-ptab@perkinscoie.com](mailto:jones-ptab@perkinscoie.com); [tietz-ptab@perkinscoie.com](mailto:tietz-ptab@perkinscoie.com); [lembo-ptab@perkinscoie.com](mailto:lembo-ptab@perkinscoie.com); [Semaglutide-Ozempic@perkinscoie.com](mailto:Semaglutide-Ozempic@perkinscoie.com); Beel, Bryan D. (Perkins Coie) <[BBeel@perkinscoie.com](mailto:BBeel@perkinscoie.com)>  
**Subject:** RE: IPR2023-00724

Megan,

Mylan does not agree to provide a *Sotera* stipulation. The trial date in the Ozempic district court litigation was ordered in June 2022 (22-cv-294, DI 22) and was explicitly disclosed and discussed in the Petition (Pet. at 65; Ex. 1082 (Scheduling Order)). Mylan addressed *Fintiv* in its Petition, yet the Patent Owner chose not to address that issue in its Preliminary Response. Moreover, the time to seek rehearing of the institution decision passed a month ago, and there has been no joinder of any proceeding with Mylan's Petition, so there are no "new facts" to address. We can be available to meet and confer on November 22, if necessary. To the extent Novo intends to seek any relief from the Board, please provide your position before contacting the Board so we may add Mylan's position.

Best regards,  
Bryan

**Bryan Beel, Ph.D. | Perkins Coie LLP**  
SENIOR COUNSEL  
1120 N.W. Couch Street Tenth Floor  
Portland, OR 97209-4128  
D. +1.503.727.2116  
F. +1.503.346.2116  
E. [BBeel@perkinscoie.com](mailto:BBeel@perkinscoie.com)

---

**From:** Megan Raymond <[megan.raymond@groombridgewu.com](mailto:megan.raymond@groombridgewu.com)>  
**Sent:** Thursday, November 16, 2023 11:44 AM  
**To:** White, Brandon (WDC) <[BMWhite@perkinscoie.com](mailto:BMWhite@perkinscoie.com)>; \*White-ptab <[White-ptab@perkinscoie.com](mailto:White-ptab@perkinscoie.com)>; \*Greb-ptab <[Greb-ptab@perkinscoie.com](mailto:Greb-ptab@perkinscoie.com)>; \*prochnow-ptab <[prochnow-ptab@perkinscoie.com](mailto:prochnow-ptab@perkinscoie.com)>; \*Jones-ptab <[jones-ptab@perkinscoie.com](mailto:jones-ptab@perkinscoie.com)>; \*tietz-ptab <[tietz-ptab@perkinscoie.com](mailto:tietz-ptab@perkinscoie.com)>; \*lembo-ptab <[lembo-ptab@perkinscoie.com](mailto:lembo-ptab@perkinscoie.com)>; \*Semaglutide-Ozempic <[Semaglutide-Ozempic@perkinscoie.com](mailto:Semaglutide-Ozempic@perkinscoie.com)>  
**Cc:** [Novo-Semaglutide-IPR@groombridgewu.com](mailto:Novo-Semaglutide-IPR@groombridgewu.com)  
**Subject:** IPR2023-00724

Counsel,

Since the time of institution of the '462 IPR, two copycat petitions have been filed (which would remove the one-year statutory deadline for the issuance of the final written decision in Mylan's IPR) and Mylan's '462 trial date has been set for September 30, 2024. In view of these circumstances, and the *Fintiv* issues that are now implicated, we write to ask whether Mylan would agree to provide a *Sotera* stipulation rather than just the *Sand Revolution* stipulation it previously furnished. Please let us know by Monday, and whether you wish to have a telephonic meet and confer. If Mylan is not amenable to providing a *Sotera* stipulation, Petitioner will seek leave to file a request for rehearing now to brief *Fintiv* issues in view of the latest facts, and request that the IPR be uninstituted.

Sincerely,  
Megan Raymond

This message is intended only for the use of the addressee and may contain confidential and privileged information. Any review, use, or dissemination by anyone other than the addressee is strictly prohibited. If you received this message in error, please notify us and delete all copies of this message.